Literature DB >> 19366348

Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Elias Fattal1, Gillian Barratt.   

Abstract

Antisense oligonucleotides and small interfering RNA have enormous potential for the treatment of a number of diseases, including cancer. However, several impediments to their widespread use as drugs still have to be overcome: in particular their lack of stability in physiological fluids and their poor penetration into cells. Association with or encapsulation within nano- and microsized drug delivery systems could help to solve these problems. In this review, we describe the progress that has been made using delivery systems composed of natural or synthetic polymers in the form of complexes, nanoparticles or microparticles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366348      PMCID: PMC2697810          DOI: 10.1111/j.1476-5381.2009.00148.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  158 in total

1.  Antisense and antigene properties of peptide nucleic acids.

Authors:  J C Hanvey; N J Peffer; J E Bisi; S A Thomson; R Cadilla; J A Josey; D J Ricca; C F Hassman; M A Bonham; K G Au
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

2.  Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties.

Authors:  P Couvreur; B Kante; M Roland; P Guiot; P Bauduin; P Speiser
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

3.  Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.

Authors:  R Y Walder; J A Walder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

4.  Sequence-specific cleavage of double helical DNA by triple helix formation.

Authors:  H E Moser; P B Dervan
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

Review 5.  LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.

Authors:  Birte Vester; Jesper Wengel
Journal:  Biochemistry       Date:  2004-10-26       Impact factor: 3.162

6.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

Authors:  L A Yakubov; E A Deeva; V F Zarytova; E M Ivanova; A S Ryte; L V Yurchenko; V V Vlassov
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Characterization of oligonucleotide transport into living cells.

Authors:  S L Loke; C A Stein; X H Zhang; K Mori; M Nakanishi; C Subasinghe; J S Cohen; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.

Authors:  R C Lee; R L Feinbaum; V Ambros
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

10.  Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides.

Authors:  C Chavany; T Le Doan; P Couvreur; F Puisieux; C Hélène
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

View more
  20 in total

1.  Editors' pick 2009.

Authors:  A Somogyi; Y K Loke; A Ferro; L D Lewis; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

2.  Delivery of magic bullets: on the still rocky road to gene therapy.

Authors:  K Takeda
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

3.  Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Authors:  Janeen H Trembley; Gretchen M Unger; Vicci L Korman; Diane K Tobolt; Zygmunt Kazimierczuk; Lorenzo A Pinna; Betsy T Kren; Khalil Ahmed
Journal:  Cancer Lett       Date:  2011-10-12       Impact factor: 8.679

4.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

Review 5.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Authors:  Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

Review 7.  Nano-ART and NeuroAIDS.

Authors:  Malay K Das; Anupam Sarma; Tapash Chakraborty
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

8.  Encapsulation of nor-β-lapachone into poly(d,l)-lactide-co-glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines.

Authors:  Marcília P Costa; Anderson C S Feitosa; Fátima C E Oliveira; Bruno C Cavalcanti; Gleiston G Dias; Ewerton W S Caetano; Francisco A M Sales; Valder N Freire; Stefano Di Fiore; Rainer Fischer; Luiz O Ladeira; Eufrânio N da Silva Júnior; Claudia Pessoa
Journal:  Medchemcomm       Date:  2017-09-07       Impact factor: 3.597

Review 9.  Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.

Authors:  Leila Farahmand; Behrad Darvishi; Keivan Majidzadeh-A
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 10.  miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents.

Authors:  Volker Baumann; Johannes Winkler
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.